Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | GFER | P55789 | 1/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ME2 | P23368 | 1/20 | 0.51 |
| ▸ | ME1 | P48163 | 1/20 | 0.51 |
| ▸ | ME3 | Q16798 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773552 | 0.99 | GFER (0.72) | SMN1; SMN2GFERHRH3ALDH1A1MAPT | |
| SCHEMBL3767730 | 0.96 | GFER (0.72) | SMN1; SMN2GFERHRH3ALDH1A1MAPT | |
| SCHEMBL3774550 | 0.93 | GFER (0.67) | SMN1; SMN2GFERHRH3ALDH1A1MAPT | |
| SCHEMBL3773709 | 0.89 | GFER (0.54) | SMN1; SMN2GFERHRH3ALDH1A1MAPT | |
| SCHEMBL3776110 | 0.88 | MEN1 (0.61) | SMN1; SMN2GFERALDH1A1MAPTKMT2A | |
| SCHEMBL3780648 | 0.88 | MAPT (0.54) | SMN1; SMN2GFERHRH3ALDH1A1MAPT | |
| SCHEMBL3767518 | 0.88 | LMNA (0.57) | SMN1; SMN2GFERHRH3ALDH1A1MAPT | |
| SCHEMBL3767578 | 0.88 | ALDH1A1 (0.72) | SMN1; SMN2GFERHRH3ALDH1A1MAPT | |
| SCHEMBL3766138 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2GFERHRH3ALDH1A1MAPT | |
| SCHEMBL3773736 | 0.87 | MEN1 (0.72) | SMN1; SMN2GFERALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | SMN1; SMN2 4282/4885GFER 3130/4885HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.